International Clinical Trial: Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739888) titled 'Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation' on July 28.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Novartis Pharmaceuticals

Condition: Atrial Fibrillation (AF)

Intervention: Biological: Abelacimab

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: December 30, 2027

Target Sample Size: 2500

To know more, visit https://clinicaltrials.g...